Johnson & Johnson paused enrollment in a Phase 2b trial of an AC Immune-partnered Alzheimer's candidate amid reported recruitment challenges.
Longevity News
Johnson & Johnson has paused further enrollment in a phase 2b trial of its AC Immune-partnered Alzheimer’s disease ca...
Source: FierceBiotech - All • Published: 19 Feb 2026, 15:24
Continue exploring
Related longevity signals
Frontiers - HealthInterplay between monocyte subsets and leukemic blasts shapes the immune microenvironment and sustains minimal residual disease in pediatric B-cell acute lymphoblastic leukemiaReports single-cell and clinical analyses linking monocyte subset shifts and IFN-responsive leukemic clones to persistent minimal residual disease in pediatric B-ALL.Frontiers - HealthThe Application Progress of Artificial Intelligence in the Diagnosis of Alzheimer's DiseaseSurvey of how machine learning and deep learning are being applied to neuroimaging and multi-omics for earlier, automated Alzheimer's diagnosis and staging.Fight Aging!Trial Results for a PD-L1 Antibody Therapy to Reduce Inflammation in Alzheimer's DiseaseA preview of an article about a clinical trial testing a PD‑L1 antibody as an anti‑inflammatory approach for early Alzheimer's disease, inviting readers curious about novel therapeutic strategies.Frontiers - HealthImpact of Anatomic Complexity of Congenital Heart Disease on Growth Retardation: A Large Retrospective Cohort StudyAssessing how anatomic complexity in congenital heart disease relates to growth retardation in a large pediatric retrospective cohort and a predictive nomogram.